TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Remission frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concordance between potential side effects and treatment choice
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Safety and acceptability profile of dextrin sulphate gel
Endpoint domain: Adverse events/effects
Primary endpoint: Change in mammographic density
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Leg endurance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diminished abduction and external rotator function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Refractive accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Minimal luminal diameter (MLD) at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: IH volume increase from 6 months to 2 years
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Late target lesion revascularization
Endpoint domain: Adverse events/effects
Primary endpoint: percentage of correct compressions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cognitive attention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Verbal episodic memory
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Total cerebral emboli load
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of maternal nausea
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of maternal vomiting
Endpoint domain: Adverse events/effects
Primary endpoint: Teletreatment user acceptance rates
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incidence of postoperative bile leakage
Endpoint domain: Adverse events/effects
Primary endpoint: perceived feelings of energy
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Future maximum symptom days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Future exacerbations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total menstrual fluid PGF2alpha
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PGF2alpha concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visible color changes (DeltaE>3)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vickers hardness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Saliva flow rates (unstimulated and stimulated)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in pH from unstimulated to stimulated saliva
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of overweight or obesity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Efficacy and safety of epinephrine and dopamine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of anemia (hemoglobin < 110 g/L)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of serum ferritin < 12 mug/L
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of serum soluble transferrin receptor > 3.3 mg/L
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hs-CRP levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: homocysteine levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: N-acetylaspartate/creatine+phosphocreatine ratios
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Wound surface area reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decreasing portal pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of PST
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative pregnancy rates
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Mean maximal flow rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: haemoglobin oxygen saturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Blood Pressure Changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Effective cure rate
Endpoint domain: Mortality/survival
Primary endpoint: Mycological cure rate
Endpoint domain: Mortality/survival
Primary endpoint: Probability of becoming pregnant
Endpoint domain: Life impact
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Mean ΔDAS28 after 28 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in the number of bacterial colonies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Nursing home days
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Incidence of severe toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency of overall adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Histologic yield
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tolerability of PP 1420
Endpoint domain: Adverse events/effects
Primary endpoint: Heart rate after 30 min
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Viral load suppression rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Toxicity-related drug switches
Endpoint domain: Adverse events/effects
Primary endpoint: spherical equivalent cycloplegic autorefraction change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: stop-signal reaction times
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Conduction velocity of motor nerves
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Speed of sound and stiffness index T- and Z-score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Breast cancer risk based on SOS and T-score quartiles
Endpoint domain: Mortality/survival
Primary endpoint: Feedback scale mean
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: end-systolic and end-diastolic left ventricular volumes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: norepinephrine levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: PD motor symptoms improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HUVECs migration ability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VE-cadherin mRNA expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absolute serum uric acid values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Capsaicin detection thresholds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of post-operative pulmonary complications
Endpoint domain: Adverse events/effects
Primary endpoint: self-reported caffeine consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: caffeine-related distress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: patients' subjective waiting time
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Average costs of hospitalizations and tests
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Smoking cessation measured by exhaled CO levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in plasma TAG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: radical elimination of asexual parasites
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: day 14 and 28 cure rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Clearing of HCV RNA and HBV DNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Improvement of histological activity index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Development of cirrhosis
Endpoint domain: Adverse events/effects
Primary endpoint: LDL-c reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Apolipoprotein A-1 increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Network craving scale score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IAD self‐scale table score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ZUNG SAS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of periodontopathic bacteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence of moderate/severe histologic rejection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: burning sensation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tongue protrusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cheek flexibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of parastomal hernias
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total death
Endpoint domain: Mortality/survival
Primary endpoint: Disability after a recurrent stroke
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Grade 3 neutropenia associated with fever or infection
Endpoint domain: Adverse events/effects
Primary endpoint: Primary efficacy (IIEF Q3 + Q4)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Successful intercourse rate
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Patient satisfaction with sexual life (GAQ)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Time to first serious infection
Endpoint domain: Adverse events/effects
Primary endpoint: Total number of serious infections
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in liver enzyme levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in ferritin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Sensitivity of CBCT1 system
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ASspiMRI-a scores improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: average intraoperative time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: average number of units of blood transfused postoperatively
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Varus collapse of the fracture at six months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum IgG titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: INR control improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean recall times
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: laterolateral amplitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VAS scores at rest or at movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Five year survival
Endpoint domain: Mortality/survival
Primary endpoint: postoperative risk of infection, incontinence and stricture formation
Endpoint domain: Adverse events/effects
Primary endpoint: Role Emotional score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Oropharyngeal airway volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Minimum cross-sectional area of the oropharynx
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physical difficulty
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Home Blood Pressure (HBP) reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Decrease in the number of positive cores or decrease in Gleason score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Microcirculatory flow indices of small and medium vessels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Compression rate of vertebral height
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recovery rate of kyphosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sperm production
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: expression of steroidogenic enzymes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: expression of 5alpha‐reductase type 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: TAT level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Platelets count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Upper gastrointestinal precancerous lesion detection rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Upper gastrointestinal mucosal visibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Systemic inflammatory response syndrome (SIRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: perceived pain symptoms during functional activities
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Rate of retinal reattachment with a single operation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of Care (QoC) score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Defective TNF‐α production
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Unfavourable outcome risk
Endpoint domain: Mortality/survival
Primary endpoint: Implantation rate per embryo transfer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: specific effector memory CD8(+) T cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of exchanges until dialysate leucocyte counts decreased to <100/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of exchanges until abdominal pain completely disappeared
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: perceived dyspnea during activities of daily living (ADL)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: 6‐min walk (6MW) distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum homocysteine level reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Grading of fatty liver
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Liver span
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Rate of complete or partial response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of pyrexia
Endpoint domain: Adverse events/effects
Primary endpoint: Adjusted odds ratios for DAS28 remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adjusted hazard ratios for withdrawal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean logMAR corrected distance visual acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean logMAR uncorrected distance visual acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentages within ±1.0 diopter of attempted correction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Breast cancer risk reduction
Endpoint domain: Mortality/survival
Primary endpoint: recovered patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TESS score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: total body fat content
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in PBI scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in GI scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CHEOP scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: glycoalbumin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Normalization of transaminase values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Changes in alanine aminotransferase levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Hypoxemic episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Carotid IMT progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Carotid plaque progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean number of symptomatic hypoglycaemic events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Mean duration of one symptomfree hypoglycaemic event
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Fat-adjusted SUVave
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SUVmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: bleeding volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: incidence rate of Frey's syndrome
Endpoint domain: Adverse events/effects
Primary endpoint: Time to return to baseline for PK
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the serum immunoreactive insulin concentration‐versus‐time curve (AUC(0‐t'))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tolerability of HIIP compared to SC lispro
Endpoint domain: Adverse events/effects
Primary endpoint: Success defined as no increase in symptom score and no desire to resume doxazosin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in FSFI-d score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduction of low-density lipoprotein cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: reduction of blood glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Favorable outcome (NIHSS score ≤1 at day 90)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Heart Rate Variability (HRC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Score for Neonatal Acute Physiology (SNAP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in L-dopa dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent time spent 'off'
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CAC severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: CAC presence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Basic Mobility function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Daily Activity function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bioequivalence of bisoprolol and hydrochlorothiazide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean BIS scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: recurrence rates of superficial bladder carcinoma
Endpoint domain: Mortality/survival
Primary endpoint: side effects of treatment
Endpoint domain: Adverse events/effects
Primary endpoint: therapeutic cure rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cervical levels of interleukin‐1beta, ‐6, and ‐8
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Pass rate of ears tested
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of TS audiometer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes